COMPASS Pathways Plc

Markets

Commodities

Currencies

Psychedelics Investing

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelics Investing

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelics Investing

Compass Pathways to Participate in Stifel Virtual CNS Forum

loader

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies. 

×
×